IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's disease

Expanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's

POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy.

The expanded research will explore how IGC-AD1's dual-action mechanism-combining anti-neuroinflammatory properties with amyloid- and tau-targeting effects-may slow the progression of Alzheimer's disease. These trials will evaluate critical outcomes, including cognitive function and biological markers associated with Alzheimer's, such as amyloid and tau levels, at multiple time points. Building on previously announced preclinical data showing IGC-AD1's impact on amyloid plaques and spatial memory, these investigations aim to explore its potential to influence key pathological features of Alzheimer's disease.

"We plan to initiate a new Phase 2 clinical trial for IGC-AD1 in 2025," said Ram Mukunda, CEO of IGC Pharma. "The trial underscores our commitment to advancing IGC-AD1 as a potential disease-modifying therapy for Alzheimer's. Cognitive decline is one of the most devastating aspects of Alzheimer's, severely impacting patients' memory, attention, and reasoning. By focusing on cognitive outcomes and underlying disease mechanisms such as amyloid plaques and tau tangles, we aim to address the critical unmet needs of patients and caregivers. This subsequent research phase is a significant step forward in delivering innovative treatments to those who need them most.

These new trials represent a pivotal step in advancing IGC-AD1 as a transformative Alzheimer's treatment. By exploring its potential as a disease-modifying therapy, we aim to create opportunities for strategic partnerships and licensing with major pharmaceutical companies. Our vision is to deliver innovative therapies that address the immense challenges faced by patients and caregivers while generating substantial value for our investors."